Determinations of the content of selected triptanes in drug substance and pharmaceutical dosage forms using gas chromatography and densitometry in the presence of their degradation products
Keywords:
naratriptan hydrochloride, sumatriptan TLCAbstract
Two methods were developed for the determination of naratriptan hydrochloride and sumatriptan. Their degradation products indispensable for validation of the system were obtained by degrading the substances using acid (0.1 M hydrochloric acid), base (0.1 M sodium hydroxide), oxidising agent (30% hydrogen peroxide), heat (105˚C), and VIS irradiation as the degradation agents. The first method consisted in the use of gas chromatography with flame ionisation detector. The best results were acquired using as a stationary base a capillary column HP-1 (10 mm x 0,53 mm i.d. with a film thickness of 2.65 µm) and helium as a mobile phase. The initial temperature, speed of temperature increase, pressure of the carrier gas and internal references were selected. Calibration graphs were linear in the concentration range 50–350 µg/ml (naratriptan hydrochloride) and 10–200 µg/ml (sumatriptan). The second method consisted in the densitometric evaluation of the selected compounds (naratriptan hydrochloride and sumatriptan) in the tablets after former separation using a thin – layer chromatography. Ethyl acetate – methanol – ammonium hydroxide solution (19:2:1 v/v/v) was used as a mobile phase and optical densities were measured at 225 nm (naratriptan hydrochloride) and 226 nm (sumatriptan). Calibration graphs of naratriptan hydrochloride and sumatriptan were linear in the concentration ranges respectively 0.2 – 3 µg and 0.2 - 4µg per spot. The developed methods were successfully applied for determining naratriptan hydrochloride and sumatriptan in drug substances and pharmaceutical dosage forms (Naramig tablets, Imigran suppositories, Sumamigran tablets) and good repeatability and accuracy were proved. The obtained results were subject to analysis and compared with the reference methods, i.e. pharmacopeal HPLC methods.
Downloads
References
Diamond S, Nowe spojrzenie na leczenie migreny Medycyna po dyplomie 2001; 10:9: 46-56
Tipre DN, Vavia PR, Estimation of sumatriptan succinate in pharmaceutical dosage form by spectrophotometric and HPTLC methods: Indian Drugs 1999;36(8): 501-505, wg Analitycal Abstract 2000; 62(1);01G185
Roccholz G, Ahrens B, Konig F, Schutz HW, Shuz H, Seno H, Screening and Identification of Sumatriptan and Its Main Metabolite by Means of Thin-Layer Chromathography, Ultraviolet Spectroscopy amd Gas Chromatography / Mass Spectrometry Arzneimittelforschung. 1995; 45(9):941-946
Bebawy LJ, Moustafa AA, Abo-Talib NF, Stability-indicating methods for the determination of sumatriptan succinate J. Pharm. Biomed. Anal. 2003; 32;1123-1133
Singh S, Jain R, Stability indicating HPLC method for the determination of sumatriptan succinate in pharmaceutical preparation and its application in dissolution rate studies. Indian Drugs 1997; 34(9): 527-531
Shirsat VA, Gabne SY,High performance liquid chromatographic determination of sumatriptan succinate from pharmaceutical preparation Indian Drugs 1998; 35(7): 404-407
Avadhanulu AB, Srinivas JS, Anjaneyulu Y, Reverse-phase HPLC and colorimetric determination of sumatriptan in its drug form Indian Drugs 1996; 33(7): 334-337
Femenío-Font A, Merino V, Rodila V, López-Castelano A, High-performance liquid chromatographic determination of sumatriptan after in vitro transdermal diffusion studies J. Pharm. Biomed. Anal. 2005; 37(3): 621-626
Ge Z, Tessier E, Neirinck L, Zhu Z, High performance liquid chromatographic method for the determination of sumatriptan with fluoroscence detection in human plasma J.Chromatogr. B 2004; 806;229-303
Franklin M, Odontiadis J, Clement EM, Determination of sumatriptan succinate in human plasma by high-performance liquid chromatography with coulometric detection and utilization of solid –phase extraction J.Chromatogr. B Biomed. Appl.1996; 681(2): 416-420
Dunne M, Andrew P, Fully automated assay for the determination of sumatriptan in human serum using solid-phase extraction and high-performance liquid chromatography with electrochemical detection J.Chromatogr. B Biomed. Appl. 1996; 14(6) 721
Altria KD, Fibley SD, Quantative pharmaceutical analysis by capilary electrophoresis J. Liq. Chromatogr. 1993; 16(11): 2281-2292
Vishwanathan K, Baetlett MG, Stewart JT, Determination of antimigration compounds rizatriptan, zolmitriptan, naratriptan and sumatriptan in human serum by liquid chromatography/electrospray tandem mass spectrometry Rapid Commun. Mass Spectrom 2000; 14(3):168-172
Cheng KN, Redrup MJ, Borrow A, Williams PN, Validation of a liquid chromatographic tandem mass spectrometric method for the determination of suma- triptan in human biological fluids J. Pharm. Biomed. Anal. 1998; 17(3); 399-408
McLoughlin DA, Olah TV, Ellis JD, Gilbrt JD, Halpin RA, Quantation of the 5HT1D agonist MK-462 and sumatriptan in plasma by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry J. Chromatogr. A 1996; 726(1-2):115-124
Xu XH ,Bartlett MG, Stewart JT, Determination of degradation products of sumatriptan succinate using LC-MS and LC-MS-MSJ. Pharm. Biomed. Anal. 2001; 26(3): 367-377
Dulery BD, Petty MA, Schoun J, David M, Hubert ND, A method using a liquid chromatographic-electrospray-mass spectrometric assay for the determination of antimigraine compounds: preliminary pharmacokinetics of MDL 74,721, sumatriptan and naratriptan, in rabbit J. Pharm. Biomed. Anal. 1997; 15(7): 1009-1020
European Pharmacopeia Sixth Edition. Council of Europe, Strasbourg Cedex 2008; 4315-4317
British Pharmacopeia 2010. The Stationery Office, London 2009; 2026-2030: 3114-3118
The United States. Pharmacopeia USP 32. The United States Pharmacopeial Convention, Rockville 2009; 3639-3643:3039-3042
Altria KD, McLean R, Development and optimisation of generic micellar electrokineticcapilary chromatography method to support analysis of a wide range of pharmaceuticals and excipient J. Pharm. Biomed. Anal. 1998; 18: 807-813
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2012 Medical Journal of the Rzeszow University and the National Medicines Institute, Warsaw

This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.




